Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The trial evaluates the overall tolerability of the drug and the efficacy of aerosolised
amphotericin B as a lipid complex (ABLC) for primary prophylaxis of invasive pulmonary
aspergillosis (IPA) in pediatric patients with acute leukemia undergoing intensive
chemotherapy.